CA2232682A1 - Use of prolactin as a tgf-beta antagonist - Google Patents
Use of prolactin as a tgf-beta antagonist Download PDFInfo
- Publication number
- CA2232682A1 CA2232682A1 CA002232682A CA2232682A CA2232682A1 CA 2232682 A1 CA2232682 A1 CA 2232682A1 CA 002232682 A CA002232682 A CA 002232682A CA 2232682 A CA2232682 A CA 2232682A CA 2232682 A1 CA2232682 A1 CA 2232682A1
- Authority
- CA
- Canada
- Prior art keywords
- tgf
- prolactin
- cells
- cell
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention is based upon the discovery that prolactin has been found to counter the effect that TGF-.beta. has on cells. An object of the present invention is to claim a method for treating a patient that may be suffering from a disease or disorder which is associated with the presence of TGF-.beta., by administering an effective amount of a pharmaceutically acceptable composition containing prolactin.
Description
USE OFPROLACl~N AS A TGF-~ETA ANTAGON~ST
Background of the Invention Transforming growth factor-,B (TGF-O belongs to a family of polypeptide factors that share certain structural and functional characteristics (Massague et al., Cell, 49:437 (1987)). Other members include the activins, the inhibins, MiillPri~n inhibiting substance (MIS), bone morphogenic proteins (BMPs) and the decapentaplegic gene product (DPP-C) found in Drosophila.
Transforming growth factor-ot is an unrelated peptide that shares a high degree of homology with epidermal growth factor (EGF), and binds the same receptor (Todaro et al., Proc. Natl. Acad. Sci. USA, 77:5258 (1980)).
TGP-,B was discovered as a product of murine sarcoma virus-transformed cells (Delarco et al., Proc. Natl. Acad. Sci. USA, 75:4001 (1978)). TGF-~ is produced by a large number of cell types, including fibroblasts, myocytes, chondrocytes (Jakowlew et al., J. Cell. Physiol., 150:377 (1992)), astrocytes (da Cunha et al., J. Neuroimmunol., 3~:157 (1992)), and epithelial cells (Steigerwalt et al., Mol. Carcin., 5:32 (1992)).
Named in accordance with its ability to stimulate anchorage-independent growth of normal fibroblasts, TG~-,13 has also been isolated from other sources, including a human glioblastoma, where it was identified as tumor-inducing factor-1 (TIF-1) (Iwata et al., Cancer Res., 45:2689 (1985)) and bovine bone, from which two cartilage-inducing factors (CI~-A and C~F-B) have been purified (Seyedin et aZ., Proc. Natl. Acad. Sci. USA, 82:2267 (1985)). Sequence information has SlJ~5 ~ ITE SHEET (RULE 26) W 097/40848 PCTrUS97107310 Proc. Natl. Acad. Sci. USA, 82:2267 (1985)). Sequence information has established that CIF-A is identical to TGF-,~1 and that CIF-B represents a second isoform, TGF-,~2. TGF-~13 is likely to be identical to Dicidual Suppressor Factor (DSF) (Lea et al., J. Immunol., 148:778 (1992)~.
There are several well-defined isoforms of TGF-,13; these disulfide-linked homodimers are designated numerically as TGF-~1 through TGF-,~5. A heterodimer, TGF-,131.2, has been identified in porcine platelets. TGF-bl and TGF-~2 are produced in many cell types, while TGF-,~3 is mainly expressed by cells of mesenchymal origin ~Roberts and Sporn in Human Cytokines, Blackwell Scientific, p. 399 (1992);
Lyons and Moses, Eur. ~. Biochem., 187:467 (1990); Derynck et ~l., EMBO
J., 7:3737 (1988); and Massague, Ann. Rev. Cell Biol., 6:597 (1990)). The amino acid homology between isoforms ranges from 70% (,131 versus ~2) to 79% (,~2 versus ,~3). Each of the TGF-,B1, TGF-,~2 and TGF-~3 isoforms displays greater than 98% amino acid sequence homology between species (Massague (1990); and Kondiah et al., J. Biol. Chem., 265:1089 (1990)). Detection of the TGF-,B4 and TGF-~5 isoforms have been limited to chick embryo chondrocytes and Xenopus embryos, respectively (l~oberts and Sporn in Human Cytokines, (1992)).
The isoforms of TGF-~ are synthesized as larger protein precusors.
Proteolytic cleavage at a site of basic amino acid residues yields the mature monomer consisting of the C-terminal 112-114 amino acids. A
biologically inactive latent complex is formed from the non-covalent association of the mature TGF-,~ dimer and two prosegments that interact non-covalently (the latency associated protein, LAP) (Roberts and Sporn in Human Cytokines, (1992); Lyons and Moses (1990)).
SllJt~ 111 ~JTE SHE~T (RULE 26) CA 02232682 1998-03-l9 W 097/40848 PCT~US97/07310 Subsequent to secretion from the cell source, activation must occur torelease the biologically active dimer form. Whereas acidification can release the TGF-,B dimer in vitro, in vivo activation is still a subject of research.
The biologically active TGP-~ isoforms are all 25 kD dimers, which, under reducing conditions, yield monomers of 11.5 to 12.5 kD.
Whereas the TGF-b precursor contains 3 to 4 N-glycosylation sites, none are present on the monomers constituting the mature TGF-,B
dimer. There are nine cysteines per monomer of mature TGF-,13 (Roberts and Sporn in Human Cytokines (1992)). Chou-Fasman analysis of TGF-,13 suggest~ an extensive b-sheet structure with very little a-helical character (Garnier et al., J. Mol. Biol., 120:97 (1978)).
A number of TGF-~ receptors mediate the biological effects of the TGF-,B dimer. Pive TGF-,B receptors have been identified ~ type I (53-65 kD), type II (83-110 l~D), type m (250-31~ kD), type IV (60 kD), and type V (400 kD) receptors (Segarini, Clinical Applications of TGF-b. Wiley, p. 29 (1991); O'Grady et aZ., ~. Biol. Chem., 266:8563 (1991); Massague, Cell, 69:1067 (1992).; and Cheifetz et al., J. Biol. Chem., 263:17225 (1988)). The type I, II, III and V receptors are co-expressed on most cells examined, with the exception of a few tumor lines. The type IV receptor has been identified only on pituitary cells (Cheifetz (1988)). Since loss of cellular response to TGF-~ correlates with loss of type I and/or type II receptors (Laiho et al., J. Biol. Chem., 266:9108 (1992)), these have been studied in the greatest detail.
Differential affinities of the receptors for TGF-,~1, TGF-~2 and TGF-~133 exist between receptor types. For example, the majority of type I and II
SU~ I UTE SHE~:T (RULE 26) CA 02232682 l998-03-l9 W O 97/40848 PCTrUS97/07310 receptors bind TGF-,131 and TGF-,(33 with greater affinity than TGF-,132 (Massague (1992)). However, there is no direct relationship between binding affinity and biological potency since TGE~-,132 is equipotent to TGF-,1~1 in many biological assays. Isoform potency is linked to many factors, including the combination of receptor types present, the number of each receptor type present, and the presence of type I and type II receptor subsets that bind all three isoforms with equal affinity (Massague (1992); Cheifetz (1988); ~aiho (1992); and Cheifetz et al., J.
Biol. Chem., 265:20533 (1990)).
The cloning of the type II receptor demonstrated that the cytoplasmic domain contains a functional serine/threonine kinase (T in et al., Cell, 68:775 (1992)). Cloning of the type III receptor demonstrated that the betaglycan structure contains a short cytoplasmic domain without a signaling motif (Wang et al., Cell, 67:797 (1991)). The type III receptor may function as a reservoir for surplus TGF-b or as a regulator of ligand-binding ability or surface expression of the type I or II receptors (Wang (1991)). Cloning of the other TGF-,13 rec~lol~ is necessary to determine whether they share a similAr pattern of phosphorylation with the type II receptor. Other observations providing insight to the TGF-b signaling mechanism include:
1. induction of changes in Jun B, c-fos, and c-myc expression (Ohtsuki et al., Mol. Cell. Biol., 12:261 (1992));
Background of the Invention Transforming growth factor-,B (TGF-O belongs to a family of polypeptide factors that share certain structural and functional characteristics (Massague et al., Cell, 49:437 (1987)). Other members include the activins, the inhibins, MiillPri~n inhibiting substance (MIS), bone morphogenic proteins (BMPs) and the decapentaplegic gene product (DPP-C) found in Drosophila.
Transforming growth factor-ot is an unrelated peptide that shares a high degree of homology with epidermal growth factor (EGF), and binds the same receptor (Todaro et al., Proc. Natl. Acad. Sci. USA, 77:5258 (1980)).
TGP-,B was discovered as a product of murine sarcoma virus-transformed cells (Delarco et al., Proc. Natl. Acad. Sci. USA, 75:4001 (1978)). TGF-~ is produced by a large number of cell types, including fibroblasts, myocytes, chondrocytes (Jakowlew et al., J. Cell. Physiol., 150:377 (1992)), astrocytes (da Cunha et al., J. Neuroimmunol., 3~:157 (1992)), and epithelial cells (Steigerwalt et al., Mol. Carcin., 5:32 (1992)).
Named in accordance with its ability to stimulate anchorage-independent growth of normal fibroblasts, TG~-,13 has also been isolated from other sources, including a human glioblastoma, where it was identified as tumor-inducing factor-1 (TIF-1) (Iwata et al., Cancer Res., 45:2689 (1985)) and bovine bone, from which two cartilage-inducing factors (CI~-A and C~F-B) have been purified (Seyedin et aZ., Proc. Natl. Acad. Sci. USA, 82:2267 (1985)). Sequence information has SlJ~5 ~ ITE SHEET (RULE 26) W 097/40848 PCTrUS97107310 Proc. Natl. Acad. Sci. USA, 82:2267 (1985)). Sequence information has established that CIF-A is identical to TGF-,~1 and that CIF-B represents a second isoform, TGF-,~2. TGF-~13 is likely to be identical to Dicidual Suppressor Factor (DSF) (Lea et al., J. Immunol., 148:778 (1992)~.
There are several well-defined isoforms of TGF-,13; these disulfide-linked homodimers are designated numerically as TGF-~1 through TGF-,~5. A heterodimer, TGF-,131.2, has been identified in porcine platelets. TGF-bl and TGF-~2 are produced in many cell types, while TGF-,~3 is mainly expressed by cells of mesenchymal origin ~Roberts and Sporn in Human Cytokines, Blackwell Scientific, p. 399 (1992);
Lyons and Moses, Eur. ~. Biochem., 187:467 (1990); Derynck et ~l., EMBO
J., 7:3737 (1988); and Massague, Ann. Rev. Cell Biol., 6:597 (1990)). The amino acid homology between isoforms ranges from 70% (,131 versus ~2) to 79% (,~2 versus ,~3). Each of the TGF-,B1, TGF-,~2 and TGF-~3 isoforms displays greater than 98% amino acid sequence homology between species (Massague (1990); and Kondiah et al., J. Biol. Chem., 265:1089 (1990)). Detection of the TGF-,B4 and TGF-~5 isoforms have been limited to chick embryo chondrocytes and Xenopus embryos, respectively (l~oberts and Sporn in Human Cytokines, (1992)).
The isoforms of TGF-~ are synthesized as larger protein precusors.
Proteolytic cleavage at a site of basic amino acid residues yields the mature monomer consisting of the C-terminal 112-114 amino acids. A
biologically inactive latent complex is formed from the non-covalent association of the mature TGF-,~ dimer and two prosegments that interact non-covalently (the latency associated protein, LAP) (Roberts and Sporn in Human Cytokines, (1992); Lyons and Moses (1990)).
SllJt~ 111 ~JTE SHE~T (RULE 26) CA 02232682 1998-03-l9 W 097/40848 PCT~US97/07310 Subsequent to secretion from the cell source, activation must occur torelease the biologically active dimer form. Whereas acidification can release the TGF-,B dimer in vitro, in vivo activation is still a subject of research.
The biologically active TGP-~ isoforms are all 25 kD dimers, which, under reducing conditions, yield monomers of 11.5 to 12.5 kD.
Whereas the TGF-b precursor contains 3 to 4 N-glycosylation sites, none are present on the monomers constituting the mature TGF-,B
dimer. There are nine cysteines per monomer of mature TGF-,13 (Roberts and Sporn in Human Cytokines (1992)). Chou-Fasman analysis of TGF-,13 suggest~ an extensive b-sheet structure with very little a-helical character (Garnier et al., J. Mol. Biol., 120:97 (1978)).
A number of TGF-~ receptors mediate the biological effects of the TGF-,B dimer. Pive TGF-,B receptors have been identified ~ type I (53-65 kD), type II (83-110 l~D), type m (250-31~ kD), type IV (60 kD), and type V (400 kD) receptors (Segarini, Clinical Applications of TGF-b. Wiley, p. 29 (1991); O'Grady et aZ., ~. Biol. Chem., 266:8563 (1991); Massague, Cell, 69:1067 (1992).; and Cheifetz et al., J. Biol. Chem., 263:17225 (1988)). The type I, II, III and V receptors are co-expressed on most cells examined, with the exception of a few tumor lines. The type IV receptor has been identified only on pituitary cells (Cheifetz (1988)). Since loss of cellular response to TGF-~ correlates with loss of type I and/or type II receptors (Laiho et al., J. Biol. Chem., 266:9108 (1992)), these have been studied in the greatest detail.
Differential affinities of the receptors for TGF-,~1, TGF-~2 and TGF-~133 exist between receptor types. For example, the majority of type I and II
SU~ I UTE SHE~:T (RULE 26) CA 02232682 l998-03-l9 W O 97/40848 PCTrUS97/07310 receptors bind TGF-,131 and TGF-,(33 with greater affinity than TGF-,132 (Massague (1992)). However, there is no direct relationship between binding affinity and biological potency since TGE~-,132 is equipotent to TGF-,1~1 in many biological assays. Isoform potency is linked to many factors, including the combination of receptor types present, the number of each receptor type present, and the presence of type I and type II receptor subsets that bind all three isoforms with equal affinity (Massague (1992); Cheifetz (1988); ~aiho (1992); and Cheifetz et al., J.
Biol. Chem., 265:20533 (1990)).
The cloning of the type II receptor demonstrated that the cytoplasmic domain contains a functional serine/threonine kinase (T in et al., Cell, 68:775 (1992)). Cloning of the type III receptor demonstrated that the betaglycan structure contains a short cytoplasmic domain without a signaling motif (Wang et al., Cell, 67:797 (1991)). The type III receptor may function as a reservoir for surplus TGF-b or as a regulator of ligand-binding ability or surface expression of the type I or II receptors (Wang (1991)). Cloning of the other TGF-,13 rec~lol~ is necessary to determine whether they share a similAr pattern of phosphorylation with the type II receptor. Other observations providing insight to the TGF-b signaling mechanism include:
1. induction of changes in Jun B, c-fos, and c-myc expression (Ohtsuki et al., Mol. Cell. Biol., 12:261 (1992));
2. prevention of cell-cycle dependent phosphorylation of the retinoblastoma protein (Ohtsuki (1992));
3. involvement of the guanine nucleotide-binding proteins (Diaz-Meco et al., Mol. Cell Biol., 12:302 (1992));
4. phosphatidyl inositol turnover (Segarini (1991)); and SIJ~S 111 ~JTE SHEET (RULE 26~
W 097/40848 PCTrUS97/07310 5. translocation of protein Kinase C from the cytosol to the cell membrane (Segarini (1991)).
TGF-,B functions both as an inhibitory and stimulatory factor. TGF-~1 and TGF-,~2 exert similar effects with only a few exceptions (Roberts and Sporn in Human Cytokines (1992); Rizzino, Dev. Biol., 130:411 (1988); Weinberg et al., J. Immunol., 148:21~9 (1992)).
Stimulatory activities include:
1. stimulation of fibroblast and osteoblast proliferation;
2. enhancement of matrix protein synthesis by fibroblasts, osteoblasts, and endothelial cells;
3. induction of cytokine production by monocytes;
4. promotion of fibroblast, monocyte and neutrophil chemotaxis;
5. enhancement of in vivo effector function and memory phenotype of antigen-specific T helper cells; and 6. stimulation of IgA secretion from B cells.
Inhibitory activities include:
1. growth inhibition of lymphocytes, endothelial cells, hepatocytes, keratinocytes and certain tumor cell lines;
2. inhibition of IgG and IgM secretion from B cells;
3. inhibition of respiratory burst capacity in monocytes;
. suppression of hematopoietic progenitors dependent on IL-3;
5. inhibition of megakaryotopoiesis;
6. inhibition of steriodogenesis in adrenocortical and Leydig cells; and, 7. inhibition of adipocyte and myocyte differentiation.
Expression of TGF-,13 isoforms in a time-dependent fashion during development and the ability to induce mesodermal marker in the SIJ~ 111 UTE SHEET ~RULE 26) _ developing Xenopus (Rosa et al., Science, 239:783 (1988)) may demonstrate a role for TGF-,~ in embryogenesis. Released at the site of a wound by platelet degranulation, TGF-,~ is reported to cause infiltration of other effector cells, protein matrix synthesis and secretion of other factors that combine with TGF-~(~ to mediate in angiogenesis, and fibrosis associated with wound healing. Similarly TGF-,13 is thought to stimulate chongrogenesis and mediate bone fracture healing.
TGF-,B has been associated with different forms of cancer (Macias et al.., Anticancer Res., 7:1271 (1987).; Shirai e~ al., Japan J Cancer Res., 83:676 (1992); Reed et al., Am J Pathology, 145:97 (1994)) and the hepatic and pulmonary disease that often developes as a complication of chemotherapy and bone marrow transplantation procedures used to treat cancer patients (Kong et al., Ann Surg 222:155 (1995); and Murase et al., Bone Marrow Transplantation, 15:173 (1994); Anscher et al. N
Eng J Med, 328:1592 (19g3). Increased TGF-,~ secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected donors has also been reported (Kekow et al., ~ Clin Invest 87:1010 (1991). Therefore, any antagonist of TGF-,B may be useful in treating these forms of cancer, as well as, may be useful in countering any of the numerous effects caused by TGF-~.
Snnlmary of the Invention This invention is based upon the discovery that prolactin has been found to counter the effect that TGF-,3 has on celIs. An object of the present invention is to claim a method for treating a patient that may be suffering from a disease or disorder which is associated with the SIJ~ ~ JTE SHEET (RULE 26) W 097/40848 PCTrUS97/07310 presence of TGP-~, by administering an effective amount of a pharmaceutically acceptable composition containing prolactin.
Another object of the present invention is to claim a method of preventing cell growth inhibition by TGF-,13 by administering an effective dose of a composition containing prolactin.
Another object of the present invention is a method of enhancing cell growth by administering an effective amount of a composition containing prolactin.
~rief Description of the Drawings Figure la illustrates the effect of TGF-,~ on hybridoma Clone 5C6.
~igure lb illustrates the effect of prolactin on hybridoma Clone 5C6.
Figure lc illustrates prolactin's ability to overcome the effects of TGF-,B
on hybridoma Clone 5C6.
Figure 2 is a table containing the results of example 2.
Figure 3 illustrates prolactin's ability to overcome the effects of TGF-~on stimulated human PBL.
Detailed Description of the Invention This invention is based upon the discovery that prolactin has been found to counter the effect of TGF-~ on cells. It was discovered that SU~ 1 UTE SHEET (RULE 26) -W 097/40848 PCTnUS97/07310 prolactin countered TGF-13 inhibitory effect on both mouse hybridoma cells and human peripheral blood mononulcear cells.
Definitions As used herein, "prolactin" refers to a polypeptide obtained from tissue cultures or by recombinant techniques and other techniques known to those of skill in the art, exhibiting the spectrum of activities characterizing this protein. The word includes not only human prolactin ~hPRL), but also other mammalian prolactin such as, e.g., mouse, rat, rabbit, primate, pig and bovine prolactin. The recombinant PRL (r-PRL) is preferred herein.
The term "recombinant prolactin", designated as r-PRL, preferably human prolactin, refers to prolactin having comparable biological activity to native prolactin prepared by recombinant DNA techniques known by those of skill in the art. ~n general, the gene coding for prolactin is excised from its native plasmid and inserted into a cloning vector to be cloned and then inserted into an expression vector, which is used to transform a host org~ni~m- The host organism expresses the foreign gene to produce prolactin under expression conditions.
As used herein, the term "patient" has its conventional meaning, i.e., one who is suffering from a disease or disorder and is under treatment for it (Stedmans Medical Dictionary, (1987)).
As used herein, the term "disease" has its conventional meaning, i.e., morbus: illness; sickness; an interruption, cessation, or disorder of the body functions, ~y~L~lns or organs (Stedmans Medical Dictionary, (1987)).
As used herein, the term "disorder" has its conventional meaning, i.e., Sl~ JTE Sl IEET (RULE 26) W 097/4~848 PCTrUS97/Q7310 a disturbance of function, stucture or both (Ste-~m~ns Medical Dictionary, (1987)).
Gene~al Method Formulations or compositions containing prolactin for counteracting the effects of TGF-,~ are most conveniently administered by injection, although other methods of administration are possible.
Standard formulations are either liquid injectables or solids which can be taken up in suitable liquids as suspensions or solutions for injection.
Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, and so forth. Nontoxic auxiliary substances, such as wetting agents, buffers, or em~ ifiers may also be added.
Sustained and continuous release formulations are of considerable variety and could be used in the method of the present invention, as is understood by those slcilled in the art.
In addition, because we have demonstrated that prolactin can counteract the effects of TGF-13, it is believed that the exogenous administration of the prolactin gene would result in the expression of prolactin in vivo which would be availal~le to function to counteract TGF-,~ whether administered through conventional means or via gene inoculation. The gene sequence for prolactin is disclosed in (U.S.
Patent No. 4,725,549). This could be produced by inserting prolactin ~ cDNA into a DNA delivery vehicle (e.g., plasmid vectors, liposomes, viral vectors). This could be accomplished as described by Pellegrini I., et al., Molec. Endocrinolgy, 6, 1023 (1992), Maniatis T., et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press (1489) and Eelger P., et al., Proc. Natl. Acad. Sci., 84, 7413, (1991).
SIJ~;~ JTE SHEET (RULE 26) 8 PCTrUS97/07310 l~XEMPLIFICAl'ION
Fx~n~ple 1: Dose Response of TGF-,B and PRL
Mouse hybridoma cell lines (including 5C6) were maintained in Hybridoma Growth Media (HGM3 consisting of 25% DMEM (Gibco), 40% NSO conditioned media, 10% NCTC 109 (Gibco), 15% FCS (Gibco), 0.1% ITS (Sigma I-1884), 0.05 mM 2-mercaptoethanol, 2 mM L-glutamine (Gibco), 10% ORIGIN (Igen, Inc.). The cells were fed the day before use to ensure log phase growth The day of assay, cells were pipetted into 15 mL conical tubes and centrifuged at 1000 rpm for 8 minutes. The media was aspirated from the cells and they were washed twice with 5 mL of assay media consisting of 88% RPMI-1640 (Gibco), 10% FCS (Gibco), 2 mM L-Glutamine, 0.05 mM 2-mercaptoethanol, 100 U/mLPen/Strep (Gibco).
The cells were resuspended in 2 mL of RPMI-1640 assay media, counted, and diluted with assay media to 2 x 105 cells/mL. A volume of 100yL of cells was pipetted into wells of a 96-well sterile tissue culture plate. The plate was placed into a 37~C incubator until use.
A dilution series of recombinant human prolactin (Genzyme Corporation, lot 02A, 800 llg/mL) and TGF-b (Genzyme Corporation, lot 94F003, 96,ug/mL) were prepared in assay media. Twenty-five microliters of each reagent was added to appropriate wells. In all cases, the TGF-,13 was added first.
The cells were incubated at 37~C/5% CO2 for 72 hours and the amount of proliferation measured by tritiated thymidine incorporation.
Tritiated thymidine (0.5,uCi) was added for the last 18 hours. Cell-associated radioactivity was measured by scintillation counting (1205 Sl~S 111 ~JTE SHEET ~RULE 26) W O 97/40848 PCTrUS97/07310 Betaplate LSC, Wallac) after harvesting the cells onto glass fiber filters using a TOMEC Harvestor 96 .
The results are shown in Figures la-c. Figure la provides a graph demonstrating the dose-response for TGF-,B on the proliferation of hybridoma cell. TGF-,~ can significantly inhibit the growth of these cells in a dose dependent manner.
Figure lb demonstrates the dose response of r-hPRL on this cell line.
The molecule clearly stimulates the proliferation of these cells in a dose dependent manner.
Figure lc demonstrates the effect of incubating various concentrations of r-hPRL with 0.4 llg/mL TGF-,~, a concentration of TGF-,~ which was demonstrated to inhibit proliferation by > 50% on these cells. r-hPRL
antagonized the suppressive effect of TGF-,B on these cells in a dose related manner.
~xample 2: ~ffect of TGF-~ and PRL on Murine Hybridoma Clones Mouse hybridoma cell lines were maintained in Hybridoma Growth Media (~GM) as described above. The day of assay, cells were pipetted into 15 mL conical tubes and centrifuged at 1000 rpm for 8 minutes.
The media was aspira~ed from u~e cells and u~ley -w-ere w-ashed ~w-ice with 5 mL of assay media consisting of 88% RPMI-1640 (Gibco), 10%
FCS (Gibco), 2 mM ~-Glutamine, 0.05 mM 2-mercaptoethanol, 100 U/mLPen/Strep (Gibco~. The cells were resuspended in 2 mL of RPMI-1640 assay media, counted, and diluted with assay media to 2 x 105cells/mL. A volume of 100~L of cells was pipetted into wells of a 96-SUBSTITUTE SHEET ~RULE 26~
W 097/40848 PCT~US97/07310 well sterile tissue culture plate and were placed into a 37~C incubator until use.
A ten-fold dilution series of TGF-,~ (Genzyme Corporation, lot 94F003, -96~g/mL) was prepared in assay media and twenty five microliters added to ~ro~Liate wells. Subsequently, 1~ug of PRL was added to the wells and the cells were incubated at 37~C/5% CO2 for 72 hours.
Tritiated thymidine (0.5~Ci) was added for the last 18 hours. The amount of proliferation measured by tritiated thymidine incorporation was measured by scintillation counting (1205 Betaplate LSC, Wallac) after harvesting the cells onto glass fiber filters using a TOMEC
Harvestor 96 .
The results are shown in the Table (Figure 2). The hybridomas varied in their sensitivity to TGF-,13, but in all cases, a decrease in cell proliferation was observed in the presence of TGF-13. Prolactin's ability to overcome TGF-,~ suppressive effects was in part dependent upon the concentration of TGF-,~. Prolactin was observed to overcome TGF-,13's suppressive with all the hybridomas (8/8) incubated with 0.1 ,ug TGF-~, with 7/8 hybridomas incubated with 1 llg TGF-,13, and with 5/8 hybridomas incubated with 10 llg TGF~
Fxample 3: l~ffect of TGF-,~ and PRL on Human Peripheral Blood Mononuclear Cells Human peripheral blood monon~ r cells (PBMC) were isolated by Picoll Paque (Pharmacia) gradient centrifugation. The cells were washed twice in PBS and resuspended in RPMI-164(~ (Gibco) media SU~ JTE SHEET (RULE 26) W O 97/40848 PCT~US97/07310 containing 1% FCS (Gibco), 2mM glutamine (Gibco~, 15mM HEPES
(Gibco), and 100 units/mL penicillin (Gibco) and 100~g/mL
streptomycin (Gibco). The cells were adjusted to a final cell density of 2X106 cell/mL and 0.1 mL was plated into wells of microtiter tissue culture plates. The cells were incubated overnight in a 37~C, 5% CO2 humidifying incubator.
The next day, 20,ug/mL PHA was added to the wells to stimulate the resting human peripheral blood lymphocytes (PBL). Immediately, TGF-~ was added to the cultures at concentrations of 0, 0.5 and 10ng/mL TGF-,B, followed by 0,10, and 2011g/mL PRL.
The cultures were incubated for 96 hours and were pulsed for the last 8 hours with 0.5~Ci Tritiated thymidine/well. The cells were harvested on a glass fiber filter using a TomTec Mach II cell harvester and - incorporated radiolabel counted using a Wallac 1205 Betaplate Counter.
The results are shown in Figure 3. Prolactin antagonized the TGF-,~
suppression of PHA stimulated human PBL.
SUBSTITUTE SHEET (RULE 26)
W 097/40848 PCTrUS97/07310 5. translocation of protein Kinase C from the cytosol to the cell membrane (Segarini (1991)).
TGF-,B functions both as an inhibitory and stimulatory factor. TGF-~1 and TGF-,~2 exert similar effects with only a few exceptions (Roberts and Sporn in Human Cytokines (1992); Rizzino, Dev. Biol., 130:411 (1988); Weinberg et al., J. Immunol., 148:21~9 (1992)).
Stimulatory activities include:
1. stimulation of fibroblast and osteoblast proliferation;
2. enhancement of matrix protein synthesis by fibroblasts, osteoblasts, and endothelial cells;
3. induction of cytokine production by monocytes;
4. promotion of fibroblast, monocyte and neutrophil chemotaxis;
5. enhancement of in vivo effector function and memory phenotype of antigen-specific T helper cells; and 6. stimulation of IgA secretion from B cells.
Inhibitory activities include:
1. growth inhibition of lymphocytes, endothelial cells, hepatocytes, keratinocytes and certain tumor cell lines;
2. inhibition of IgG and IgM secretion from B cells;
3. inhibition of respiratory burst capacity in monocytes;
. suppression of hematopoietic progenitors dependent on IL-3;
5. inhibition of megakaryotopoiesis;
6. inhibition of steriodogenesis in adrenocortical and Leydig cells; and, 7. inhibition of adipocyte and myocyte differentiation.
Expression of TGF-,13 isoforms in a time-dependent fashion during development and the ability to induce mesodermal marker in the SIJ~ 111 UTE SHEET ~RULE 26) _ developing Xenopus (Rosa et al., Science, 239:783 (1988)) may demonstrate a role for TGF-,~ in embryogenesis. Released at the site of a wound by platelet degranulation, TGF-,~ is reported to cause infiltration of other effector cells, protein matrix synthesis and secretion of other factors that combine with TGF-~(~ to mediate in angiogenesis, and fibrosis associated with wound healing. Similarly TGF-,13 is thought to stimulate chongrogenesis and mediate bone fracture healing.
TGF-,B has been associated with different forms of cancer (Macias et al.., Anticancer Res., 7:1271 (1987).; Shirai e~ al., Japan J Cancer Res., 83:676 (1992); Reed et al., Am J Pathology, 145:97 (1994)) and the hepatic and pulmonary disease that often developes as a complication of chemotherapy and bone marrow transplantation procedures used to treat cancer patients (Kong et al., Ann Surg 222:155 (1995); and Murase et al., Bone Marrow Transplantation, 15:173 (1994); Anscher et al. N
Eng J Med, 328:1592 (19g3). Increased TGF-,~ secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected donors has also been reported (Kekow et al., ~ Clin Invest 87:1010 (1991). Therefore, any antagonist of TGF-,B may be useful in treating these forms of cancer, as well as, may be useful in countering any of the numerous effects caused by TGF-~.
Snnlmary of the Invention This invention is based upon the discovery that prolactin has been found to counter the effect that TGF-,3 has on celIs. An object of the present invention is to claim a method for treating a patient that may be suffering from a disease or disorder which is associated with the SIJ~ ~ JTE SHEET (RULE 26) W 097/40848 PCTrUS97/07310 presence of TGP-~, by administering an effective amount of a pharmaceutically acceptable composition containing prolactin.
Another object of the present invention is to claim a method of preventing cell growth inhibition by TGF-,13 by administering an effective dose of a composition containing prolactin.
Another object of the present invention is a method of enhancing cell growth by administering an effective amount of a composition containing prolactin.
~rief Description of the Drawings Figure la illustrates the effect of TGF-,~ on hybridoma Clone 5C6.
~igure lb illustrates the effect of prolactin on hybridoma Clone 5C6.
Figure lc illustrates prolactin's ability to overcome the effects of TGF-,B
on hybridoma Clone 5C6.
Figure 2 is a table containing the results of example 2.
Figure 3 illustrates prolactin's ability to overcome the effects of TGF-~on stimulated human PBL.
Detailed Description of the Invention This invention is based upon the discovery that prolactin has been found to counter the effect of TGF-~ on cells. It was discovered that SU~ 1 UTE SHEET (RULE 26) -W 097/40848 PCTnUS97/07310 prolactin countered TGF-13 inhibitory effect on both mouse hybridoma cells and human peripheral blood mononulcear cells.
Definitions As used herein, "prolactin" refers to a polypeptide obtained from tissue cultures or by recombinant techniques and other techniques known to those of skill in the art, exhibiting the spectrum of activities characterizing this protein. The word includes not only human prolactin ~hPRL), but also other mammalian prolactin such as, e.g., mouse, rat, rabbit, primate, pig and bovine prolactin. The recombinant PRL (r-PRL) is preferred herein.
The term "recombinant prolactin", designated as r-PRL, preferably human prolactin, refers to prolactin having comparable biological activity to native prolactin prepared by recombinant DNA techniques known by those of skill in the art. ~n general, the gene coding for prolactin is excised from its native plasmid and inserted into a cloning vector to be cloned and then inserted into an expression vector, which is used to transform a host org~ni~m- The host organism expresses the foreign gene to produce prolactin under expression conditions.
As used herein, the term "patient" has its conventional meaning, i.e., one who is suffering from a disease or disorder and is under treatment for it (Stedmans Medical Dictionary, (1987)).
As used herein, the term "disease" has its conventional meaning, i.e., morbus: illness; sickness; an interruption, cessation, or disorder of the body functions, ~y~L~lns or organs (Stedmans Medical Dictionary, (1987)).
As used herein, the term "disorder" has its conventional meaning, i.e., Sl~ JTE Sl IEET (RULE 26) W 097/4~848 PCTrUS97/Q7310 a disturbance of function, stucture or both (Ste-~m~ns Medical Dictionary, (1987)).
Gene~al Method Formulations or compositions containing prolactin for counteracting the effects of TGF-,~ are most conveniently administered by injection, although other methods of administration are possible.
Standard formulations are either liquid injectables or solids which can be taken up in suitable liquids as suspensions or solutions for injection.
Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, and so forth. Nontoxic auxiliary substances, such as wetting agents, buffers, or em~ ifiers may also be added.
Sustained and continuous release formulations are of considerable variety and could be used in the method of the present invention, as is understood by those slcilled in the art.
In addition, because we have demonstrated that prolactin can counteract the effects of TGF-13, it is believed that the exogenous administration of the prolactin gene would result in the expression of prolactin in vivo which would be availal~le to function to counteract TGF-,~ whether administered through conventional means or via gene inoculation. The gene sequence for prolactin is disclosed in (U.S.
Patent No. 4,725,549). This could be produced by inserting prolactin ~ cDNA into a DNA delivery vehicle (e.g., plasmid vectors, liposomes, viral vectors). This could be accomplished as described by Pellegrini I., et al., Molec. Endocrinolgy, 6, 1023 (1992), Maniatis T., et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press (1489) and Eelger P., et al., Proc. Natl. Acad. Sci., 84, 7413, (1991).
SIJ~;~ JTE SHEET (RULE 26) 8 PCTrUS97/07310 l~XEMPLIFICAl'ION
Fx~n~ple 1: Dose Response of TGF-,B and PRL
Mouse hybridoma cell lines (including 5C6) were maintained in Hybridoma Growth Media (HGM3 consisting of 25% DMEM (Gibco), 40% NSO conditioned media, 10% NCTC 109 (Gibco), 15% FCS (Gibco), 0.1% ITS (Sigma I-1884), 0.05 mM 2-mercaptoethanol, 2 mM L-glutamine (Gibco), 10% ORIGIN (Igen, Inc.). The cells were fed the day before use to ensure log phase growth The day of assay, cells were pipetted into 15 mL conical tubes and centrifuged at 1000 rpm for 8 minutes. The media was aspirated from the cells and they were washed twice with 5 mL of assay media consisting of 88% RPMI-1640 (Gibco), 10% FCS (Gibco), 2 mM L-Glutamine, 0.05 mM 2-mercaptoethanol, 100 U/mLPen/Strep (Gibco).
The cells were resuspended in 2 mL of RPMI-1640 assay media, counted, and diluted with assay media to 2 x 105 cells/mL. A volume of 100yL of cells was pipetted into wells of a 96-well sterile tissue culture plate. The plate was placed into a 37~C incubator until use.
A dilution series of recombinant human prolactin (Genzyme Corporation, lot 02A, 800 llg/mL) and TGF-b (Genzyme Corporation, lot 94F003, 96,ug/mL) were prepared in assay media. Twenty-five microliters of each reagent was added to appropriate wells. In all cases, the TGF-,13 was added first.
The cells were incubated at 37~C/5% CO2 for 72 hours and the amount of proliferation measured by tritiated thymidine incorporation.
Tritiated thymidine (0.5,uCi) was added for the last 18 hours. Cell-associated radioactivity was measured by scintillation counting (1205 Sl~S 111 ~JTE SHEET ~RULE 26) W O 97/40848 PCTrUS97/07310 Betaplate LSC, Wallac) after harvesting the cells onto glass fiber filters using a TOMEC Harvestor 96 .
The results are shown in Figures la-c. Figure la provides a graph demonstrating the dose-response for TGF-,B on the proliferation of hybridoma cell. TGF-,~ can significantly inhibit the growth of these cells in a dose dependent manner.
Figure lb demonstrates the dose response of r-hPRL on this cell line.
The molecule clearly stimulates the proliferation of these cells in a dose dependent manner.
Figure lc demonstrates the effect of incubating various concentrations of r-hPRL with 0.4 llg/mL TGF-,~, a concentration of TGF-,~ which was demonstrated to inhibit proliferation by > 50% on these cells. r-hPRL
antagonized the suppressive effect of TGF-,B on these cells in a dose related manner.
~xample 2: ~ffect of TGF-~ and PRL on Murine Hybridoma Clones Mouse hybridoma cell lines were maintained in Hybridoma Growth Media (~GM) as described above. The day of assay, cells were pipetted into 15 mL conical tubes and centrifuged at 1000 rpm for 8 minutes.
The media was aspira~ed from u~e cells and u~ley -w-ere w-ashed ~w-ice with 5 mL of assay media consisting of 88% RPMI-1640 (Gibco), 10%
FCS (Gibco), 2 mM ~-Glutamine, 0.05 mM 2-mercaptoethanol, 100 U/mLPen/Strep (Gibco~. The cells were resuspended in 2 mL of RPMI-1640 assay media, counted, and diluted with assay media to 2 x 105cells/mL. A volume of 100~L of cells was pipetted into wells of a 96-SUBSTITUTE SHEET ~RULE 26~
W 097/40848 PCT~US97/07310 well sterile tissue culture plate and were placed into a 37~C incubator until use.
A ten-fold dilution series of TGF-,~ (Genzyme Corporation, lot 94F003, -96~g/mL) was prepared in assay media and twenty five microliters added to ~ro~Liate wells. Subsequently, 1~ug of PRL was added to the wells and the cells were incubated at 37~C/5% CO2 for 72 hours.
Tritiated thymidine (0.5~Ci) was added for the last 18 hours. The amount of proliferation measured by tritiated thymidine incorporation was measured by scintillation counting (1205 Betaplate LSC, Wallac) after harvesting the cells onto glass fiber filters using a TOMEC
Harvestor 96 .
The results are shown in the Table (Figure 2). The hybridomas varied in their sensitivity to TGF-,13, but in all cases, a decrease in cell proliferation was observed in the presence of TGF-13. Prolactin's ability to overcome TGF-,~ suppressive effects was in part dependent upon the concentration of TGF-,~. Prolactin was observed to overcome TGF-,13's suppressive with all the hybridomas (8/8) incubated with 0.1 ,ug TGF-~, with 7/8 hybridomas incubated with 1 llg TGF-,13, and with 5/8 hybridomas incubated with 10 llg TGF~
Fxample 3: l~ffect of TGF-,~ and PRL on Human Peripheral Blood Mononuclear Cells Human peripheral blood monon~ r cells (PBMC) were isolated by Picoll Paque (Pharmacia) gradient centrifugation. The cells were washed twice in PBS and resuspended in RPMI-164(~ (Gibco) media SU~ JTE SHEET (RULE 26) W O 97/40848 PCT~US97/07310 containing 1% FCS (Gibco), 2mM glutamine (Gibco~, 15mM HEPES
(Gibco), and 100 units/mL penicillin (Gibco) and 100~g/mL
streptomycin (Gibco). The cells were adjusted to a final cell density of 2X106 cell/mL and 0.1 mL was plated into wells of microtiter tissue culture plates. The cells were incubated overnight in a 37~C, 5% CO2 humidifying incubator.
The next day, 20,ug/mL PHA was added to the wells to stimulate the resting human peripheral blood lymphocytes (PBL). Immediately, TGF-~ was added to the cultures at concentrations of 0, 0.5 and 10ng/mL TGF-,B, followed by 0,10, and 2011g/mL PRL.
The cultures were incubated for 96 hours and were pulsed for the last 8 hours with 0.5~Ci Tritiated thymidine/well. The cells were harvested on a glass fiber filter using a TomTec Mach II cell harvester and - incorporated radiolabel counted using a Wallac 1205 Betaplate Counter.
The results are shown in Figure 3. Prolactin antagonized the TGF-,~
suppression of PHA stimulated human PBL.
SUBSTITUTE SHEET (RULE 26)
Claims (9)
1. Method for treating a patient suffering from a disease or disorder associated with TGF-.beta. by administering an effective amount of a pharmaceutically acceptable composition containing prolactin.
2. A method of preventing cell growth inhibition by TGF-.beta. by administering an effective dose of a composition containing prolactin.
3. A method of enhancing cell growth by administering an effective amount of a composition containing prolactin.
4. The methods of claims 1, 2, and 3, wherein the prolactin is human prolactin.
5. The methods of claims 1, 2, and 3, wherein the prolactin is recombinant prolactin.
6. The method of claim 1, 2, and 3, wherein the cells are lymphoid cells.
7. The method of claim 1, 2, and 3, wherein the cells are endothelial cells.
8. The method of claim 1, 2, and 3, wherein the cells are epithelial cells.
9. Method for treating a patient suffering from a disease or disorder associated with TGF-.beta. by administering an effective amount of a pharmaceutically acceptable composition containing prolactin DNA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1649296P | 1996-04-30 | 1996-04-30 | |
| US60/016,492 | 1996-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2232682A1 true CA2232682A1 (en) | 1997-11-06 |
Family
ID=21777407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002232682A Abandoned CA2232682A1 (en) | 1996-04-30 | 1997-04-30 | Use of prolactin as a tgf-beta antagonist |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0921809A4 (en) |
| JP (1) | JP2000510112A (en) |
| AU (1) | AU2749697A (en) |
| CA (1) | CA2232682A1 (en) |
| WO (1) | WO1997040848A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007050793A2 (en) | 2005-10-25 | 2007-05-03 | The Johns Hopkins University | Methods and compositions for the treatment of marfan syndrome and associated disorders |
| EP1998810A4 (en) | 2006-03-13 | 2009-09-02 | Univ Johns Hopkins | Augmentation of endothelial thromboresistance |
| HUE035575T2 (en) | 2006-10-03 | 2018-05-28 | Genzyme Corp | Use of TGF beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
| PT3117709T (en) | 2010-03-12 | 2018-11-15 | Genzyme Corp | Combination therapy for treating breast cancer |
| CN103429732B (en) | 2010-12-27 | 2015-09-16 | Lsip基金运营联合公司 | IPS cell and manufacture method thereof |
| EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
| BR112014009789A2 (en) | 2011-10-26 | 2017-04-25 | Seattle Children's Res Inst | cysteamine in the treatment of fibrotic disease |
| JP6218229B2 (en) | 2011-12-28 | 2017-10-25 | 京都府公立大学法人 | Normalization of corneal endothelial cell culture |
| US11382904B2 (en) | 2013-10-31 | 2022-07-12 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995021625A1 (en) * | 1994-02-14 | 1995-08-17 | Genzyme Corporation | Prolactin as a vaccine adjuvant |
-
1997
- 1997-04-30 EP EP97921467A patent/EP0921809A4/en not_active Withdrawn
- 1997-04-30 CA CA002232682A patent/CA2232682A1/en not_active Abandoned
- 1997-04-30 WO PCT/US1997/007310 patent/WO1997040848A1/en not_active Application Discontinuation
- 1997-04-30 JP JP09539206A patent/JP2000510112A/en active Pending
- 1997-04-30 AU AU27496/97A patent/AU2749697A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2749697A (en) | 1997-11-19 |
| EP0921809A4 (en) | 2001-10-24 |
| JP2000510112A (en) | 2000-08-08 |
| WO1997040848A1 (en) | 1997-11-06 |
| EP0921809A1 (en) | 1999-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Simorre-Pinatel et al. | Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway. | |
| Zhang et al. | Umbilical cord-matrix stem cells induce the functional restoration of vascular endothelial cells and enhance skin wound healing in diabetic mice via the polarized macrophages | |
| Cooper et al. | Acceleration of onset of collagen‐induced arthritis by intra‐articular injection of tumour necrosis factor or transforming growth factor‐beta | |
| US5612211A (en) | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors | |
| Libby et al. | Production of platelet-derived growth factor–like mitogen by smooth-muscle cells from human atheroma | |
| Gospodarowicz | Growth factors and their action in vivo and in vitro | |
| Limb et al. | Cytokines in proliferative vitreoretinopathy | |
| Roberts et al. | The transforming growth factor-β s | |
| Merwin et al. | Transforming growth factor beta1 modulates extracellular matrix organization and cell‐cell junctional complex formation during in vitro angiogenesis | |
| Righi et al. | Monokine production by microglial cell clones | |
| DE69914463T2 (en) | THERAPEUTIC CHEMOKINE RECEPTOR ANTAGONISTS | |
| US7410639B2 (en) | Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use | |
| Dr. Weir et al. | Macrophage colony‐stimulating factor release and receptor expression in bone cells | |
| DE60103052T2 (en) | USE OF CXCR4 ANTAGONISTS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | |
| JP2006087434A (en) | Novel neurotrophic factor | |
| Hou et al. | Astrogliosis in culture. IV. Effects of basic fibroblast growth factor | |
| JP2002539082A (en) | Vascular endothelial growth factor 2 | |
| PT946199E (en) | Tgf beta 1-responsive cells from bone marrow | |
| CA2232682A1 (en) | Use of prolactin as a tgf-beta antagonist | |
| US20050032697A1 (en) | Heparin binding VEGFR-3 ligands | |
| EP0437281B1 (en) | Composition comprising acidic fibroblast growth factor (aFGF) | |
| US8420780B2 (en) | Mutated netrin 4, fragments thereof and uses thereof as drugs | |
| US20080214463A1 (en) | Method for cell adhesion and wound healing | |
| WO1991018620A1 (en) | Stimulation of bone marrow stromal and progenitor cells | |
| Clark et al. | Transforming growth factor-β-like activity in tumors of the central nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |